Tomasz Ciach

Prof. Tomasz Ciach


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2016 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
IAIman Adipurnama
Iman Adipurnama
MYMing-Chien Yang
Ming-Chien Yang
TCTomasz Ciach
Tomasz Ciach
Beata Butruk-RaszejaBeata Butruk-Raszeja
Beata Butruk-Raszeja
Cardiovascular implants, especially vascular grafts made of synthetic polymers, find wide clinical applications in the treatment of cardiovascular diseases. However, cases of failure still exist, notably caused by restenosis and thrombus formation. Aiming to solve these problems, various approaches to surface modification of synthetic vascular grafts have been used to improve both the hemocompatibility and long-term patency of artificial vascular grafts. Surface modification using hydrophilic molecules can enhance hemocompatibility, but this may limit the initial vascular endothelial cell adhesion. Therefore, the improvement of endothelialization on these grafts with specific peptides and biomolecules is now an exciting field of research. In this review, several techniques to improve surface modification and endothelialization on vascular grafts, mainly polyurethane (PU) grafts, are summarized, together with the recent development and evolution of the different strategies: from the use of PEG, zwitterions, and polysaccharides to peptides and other biomolecules and genes; from in vitro endothelialization to in vivo endothelialization; and from bio-inert and bio-active to bio-mimetic approaches.

1 February 2019 in Chemical Engineering and Processing - Process Intensification
Verified
Journal Article
Closed access
KUKarol Ulatowski
Karol Ulatowski
Pawel SobieszukPawel Sobieszuk
Pawel Sobieszuk
AMAndrzej Mróz
Andrzej Mróz
TCTomasz Ciach
Tomasz Ciach

Verified
Journal Article
Open access
PDF file
AMAnna Mazurkiewicz-Pisarek
Anna Mazurkiewicz-Pisarek
JBJoanna Baran
Joanna Baran
TCTomasz Ciach
Tomasz Ciach
Antimicrobial peptides (AMPs), or host defence peptides, are short proteins in various life forms. Here we discuss AMPs, which may become a promising substitute or adjuvant in pharmaceutical, biomedical, and cosmeceutical uses. Their pharmacological potential has been investigated intensively, especially as antibacterial and antifungal drugs and as promising antiviral and anticancer agents. AMPs exhibit many properties, and some of these have attracted the attention of the cosmetic industry. AMPs are being developed as novel antibiotics to combat multidrug-resistant pathogens and as potential treatments for various diseases, including cancer, inflammatory disorders, and viral infections. In biomedicine, AMPs are being developed as wound-healing agents because they promote cell growth and tissue repair. The immunomodulatory effects of AMPs could be helpful in the treatment of autoimmune diseases. In the cosmeceutical industry, AMPs are being investigated as potential ingredients in skincare products due to their antioxidant properties (anti-ageing effects) and antibacterial activity, which allows the killing of bacteria that contribute to acne and other skin conditions. The promising benefits of AMPs make them a thrilling area of research, and studies are underway to overcome obstacles and fully harness their therapeutic potential. This review presents the structure, mechanisms of action, possible applications, production methods, and market for AMPs.

11 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IWIga Wasiak
Iga Wasiak
AKAleksandra Kulikowska
Aleksandra Kulikowska
MJMagdalena Janczewska
Magdalena Janczewska
MMMagdalena Michalak
Magdalena Michalak
ICIwona A. Cymerman
Iwona A. Cymerman
TCTomasz Ciach
Tomasz Ciach
Dextran is widely exploited in medical products and as a component of drug-delivering nanoparticles (NPs). Here, we tested whether dextran can serve as the main substrate of NPs and form a stable backbone. We tested dextrans with several molecular masses under several synthesis conditions to optimize NP stability. The analysis of the obtained nanoparticles showed that dextran NPs that were synthesized from 70 kDa dextran with a 5% degree of oxidation of the polysaccharide chain and 50% substitution with dodecylamine formed a NP backbone composed of modified dextran subunits, the mean diameter of which in an aqueous environment was around 100 nm. Dextran NPs could be stored in a dry state and reassembled in water. Moreover, we found that different chemical moieties (e.g., drugs such as doxorubicin) can be attached to the dextran NPs via a pH-dependent bond that allows release of the drug with lowering pH. We conclude that dextran NPs are a promising nano drug carrier.

16 October 2013 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
IAINAM UL AHAD
INAM UL AHAD
ABAndrzej Bartnik
Andrzej Bartnik
HFHenryk Fiedorowicz
Henryk Fiedorowicz
JKJerzy Kostecki
Jerzy Kostecki
BKBarbara Korczyc
Barbara Korczyc
Dermot BrabazonDermot Brabazon
Dermot Brabazon

29 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
Khaled AbouAitahKhaled AbouAitah
Khaled AbouAitah
ASAnna Swiderska-Sroda
Anna Swiderska-Sroda
AFAhmed A. Farghali
Ahmed A. Farghali
Jacek WojnarowiczJacek Wojnarowicz
Jacek Wojnarowicz
ASAgata Stefanek
Agata Stefanek
Witold LojkowskiWitold Lojkowski
Witold Lojkowski
Folic acid–conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action Folic acid–conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action